Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 1, 2011, Pages 89-91

  Schroner, Z ^a   Javorsky, M ^a   Tkacova, R ^a   Klimcakova, L ^b   Dobrikova, M ^a   Habalova, V ^b   Kozarova, M ^a   Zidzik, J ^b   Rudikova, M ^c   Tkac, I ^a  

^a Med Faculty of Safarik University   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c Department of Medicine   (Slovakia)

Author keywords

Glycaemic control; Metformin; Pharmacogenetics; Sulphonylureas; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; TRANSCRIPTION FACTOR 7 LIKE 2;

ADD ON THERAPY; ADULT; AGED; DRUG EFFECT; DRUG TREATMENT FAILURE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 78649693563     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01324.x     Document Type: Letter

References (12)

1. Grant RW, Moore AF, Florez JC. Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care 2009; 32: 1107-1114.
2. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116.
3. Voight BF, Scott LJ, Steinthorsdottir V et al. MAGIC investigators, GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589.
4. Tong Y, Lin Y, Zhang Y et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009; 10: 15.
5. Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241-250.
6. Saxena R, Gianniny L, Burt NP et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55: 2890-2895.
7. Pearson ER. Translating TCF7L2: from gene to function. Diabetologia 2009; 52: 1227-1230.
8. Villareal DT, Robertson H, Bell GI et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010; 59: 479-485.
9. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
10. Gribble FM, Reimann F. Sulphonylurea action revisited: the post cloning era. Diabetologia 2003; 46: 875-891.
11. Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31: 1939-1944.
12. Pearson ER, Donelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas. A GoDARTs Study. Diabetes 2007; 56: 2178-2182.